Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigation of Fenamic Acids as Blood-Brain Barrier-Permeable Beta-Amyloid Antioligomerics
EF 2015-16
Résumé
Small aggregations, or oligomers, of the amyloid-ß protein in the brain are believed to be causative agents of Alzheimer's disease, a major cause of dementia. As such, much recent research into the disease has focused on drug interactions with this protein that may affect its ability to form neurotoxic oligomers. Recent studies have established o-aminophenols as highly effective in preventing amyloid-ß from forming oligomers, but, so far, none have been evaluated for their ability to reach the brain. To enter the brain, pharmaceuticals in the bloodstream must cross the highly selectively permeable blood-brain barrier; thus, drugs intended to work in the brain must be assessed for their ability to cross this barrier.Fenamic acids are a type of compound structurally similar to o-aminophenols; I hypothesize that certain compounds like these acids may be able to traverse the barrier and inhibit amyloid-ß oligomer formation. To this end, I aim to design and synthesize fifty of these compounds, and to assess the effects of various structural modifications to them on their blood-brain barrier permeability and antioligomeric effects. I am currently screening fenamic acids and similar compounds computationally to identify those likely to exhibit the desired properties. This approach allows a large number of compounds to be screened efficiently and economically. I am also preparing these compounds to test their effectiveness using a variety of assays that simulate the blood-brain barrier and enable measurement of their effects on amyloid-ß. This research may lead to the discovery of anti-Alzheimer pharmaceuticals, and will further our understanding of amyloid-ß oligomerization and how to inhibit, prevent, or reverse it.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
349877
Name
MacMillan John W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of Fenamic Acids as Blood-Brain Barrier-Permeable Beta-Amyloid Antioligomerics
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Amyloid-Beta; Antioligomeric; Computer-Aided Drug Design; Fenamic Acid
Abstract
Small aggregations, or oligomers, of the amyloid-ß protein in the brain are believed to be causative agents of Alzheimer's disease, a major cause of dementia. As such, much recent research into the disease has focused on drug interactions with this protein that may affect its ability to form neurotoxic oligomers. Recent studies have established o-aminophenols as highly effective in preventing amyloid-ß from forming oligomers, but, so far, none have been evaluated for their ability to reach the brain. To enter the brain, pharmaceuticals in the bloodstream must cross the highly selectively permeable blood-brain barrier; thus, drugs intended to work in the brain must be assessed for their ability to cross this barrier.Fenamic acids are a type of compound structurally similar to o-aminophenols; I hypothesize that certain compounds like these acids may be able to traverse the barrier and inhibit amyloid-ß oligomer formation. To this end, I aim to design and synthesize fifty of these compounds, and to assess the effects of various structural modifications to them on their blood-brain barrier permeability and antioligomeric effects. I am currently screening fenamic acids and similar compounds computationally to identify those likely to exhibit the desired properties. This approach allows a large number of compounds to be screened efficiently and economically. I am also preparing these compounds to test their effectiveness using a variety of assays that simulate the blood-brain barrier and enable measurement of their effects on amyloid-ß. This research may lead to the discovery of anti-Alzheimer pharmaceuticals, and will further our understanding of amyloid-ß oligomerization and how to inhibit, prevent, or reverse it.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacMillan, John W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~